Navigation Links
Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
Date:12/7/2008

hemotherapy. The primary outcome of the study was the combined occurrence of clinically overt venous or arterial thromboembolic events (i.e., deep-vein thrombosis of the lower and upper limbs, visceral and cerebral venous thrombosis, pulmonary embolism, acute myocardial infarction, ischemic stroke, acute peripheral arterial thromboembolism, and unexplained death of possible thromboembolic origin). Major bleeding was the main safety parameter.

In this study, 1,166 patients with advanced lung (279), colon (235), breast (165), ovarian (143), stomach (98), rectal (87), pancreatic (53), head and neck (36), and other cancers (54) were randomized to one of two treatment arms: once-daily subcutaneous injections of nadroparin (3,000 IU) or placebo. Twice as many patients were enrolled into the nadroparin group than the placebo group. Treatment was started on the first day of the current cycle of chemotherapy and was maintained for the overall duration of chemotherapy treatment or up to a maximum of four months.

Only 16 of the 769 patients treated with nadroparin had a thromboembolic event (2.1 percent) compared with 15 of the 381 patients (3.9 percent) in the placebo group, a 47.2 percent reduction in the risk of developing a thromboembolic event for the patients in the treatment arm. The drug also appeared to be safe as only five patients in the nadroparin group (0.7 percent) experienced a major bleeding episode, and the incidence of minor bleeding in the treatment arm was similar to that of the placebo group.

Venous thromboembolism occurred 11 times in both the nadroparin and placebo groups. Fifteen of these events occurred in patients with lung cancer (4 percent in the nadroparin arm and 8.8 percent in the placebo arm). Patients with pancreatic cancer also experienced a high overall rate of thromboembolic events (7.5 percent). While this study confirms that nadroparin reduces the incidence of thromboembolic ev
'/>"/>

SOURCE American Society of Hematology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)...  Seeger Weiss LLP is reporting that on July 13, ... to C.R. Bard, the manufacturer of Inferior vena cava ... violations the agency found at two of Bard,s facilities. Bard ... cited them during Inspectional Observations that occurred on November 18, ... AZ , location and on October 6, 2014, through ...
(Date:7/31/2015)... July 31, 2015 RnRMarketResearch.com ... market research report that provides an overview of ... data sourced from in-house databases, secondary and primary ... needles market products pipeline spread across 124 pages, ... 73 tables and 5 figures is now available ...
(Date:7/31/2015)... 31, 2015 According to a new ... Heat, Dry Heat, Ethylene Oxide, Filtration, E-beam, Gamma), Services (Onsite ... Pharmaceuticals) - Global Forecast to 2020", published by MarketsandMarkets, The ... Billion by 2020, at a CAGR of 7.6%.from 2015 to ... market data T ables and 37 ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4
... 2011 Laureate Biopharmaceutical Services, Inc., a full-service ... that they have entered into a multi-year development ... company to produce a biosimilar product.  Laureate,s services ... Laureate and cGMP manufacture of this product for ...
... MOUNTAIN VIEW, Calif., July 25, 2011 Concentric Medical, Inc., ... stroke patients and distal access solutions, today announced the launch ... the fourth and largest diameter addition to the DAC family, ... commercially available. The DAC Catheter was the ...
Cached Medicine Technology:Laureate Biopharma to Produce Biosimilar Product for Leading Generics Company 2Concentric Medical Launches DAC® 070, A New Distal Access Catheter 2Concentric Medical Launches DAC® 070, A New Distal Access Catheter 3
(Date:7/31/2015)... , ... July 31, 2015 , ... ... the RenovoCath,™ a novel catheter that was developed for targeted delivery of fluids ... are now being treated at Florida Hospital Tampa with the device that provides ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Patients with higher ... to a study published today in Nature Communications and led by researchers from the ... suggests that variations in the gene RTN1 led to greater production of the related ...
(Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 hair transplant ... they are the latest recipients of the Center of Clinical Excellence for ARTAS ... worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair Restoration is ...
(Date:7/31/2015)... NB (PRWEB) , ... July 31, 2015 , ... Indosoft, ... script builder in Q-Suite 5.9. Q-Suite is their flagship contact center ACD system ... that the agent script display logic shows the script components to the agent only ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... release a newly redesigned website at Healthpointe.net. The new website will feature a ... , The redesign serves to provide smoother interactions between patients and the Healthpointe ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:Healthpointe Announces Newly Redesigned Website 2
... a technique to attack and destroy tumours without causing ... hair loss. ,They have used nanotechnology to ... leave healthy tissue unaffected. ,The particles - ... they zero in on their target. ,Traditional ...
... A chemical emergency struck Salisbury, suburb north of the Adelaide ... a five-year-old kid , sliding down in a popular ... ,It is not clear what happened to the ... out something had gone wrong. ,Health authorities described ...
... out of care do not live as long as those ... Medicine and Veterans Affairs researchers in a report published ... available on line. ,"In an era when highly ... causes AIDS) is keeping people alive, understanding the value of ...
... Britain have developed an artificial plastic blood, which they claim ... be a huge advantage in war zones. ... that have an iron atom at their core, like haemoglobin, ... researchers say they were looking for extra funding to develop ...
... for a Tasmanian school was convicted to a four-month jail ... and making pornography out of it. ,Adrian Alan ... indecency, one count of producing child exploitation material, and one ... used the school's own camera to take 36 pictures of ...
... To help people understand who is at risk for the disease, ... up some common myths about osteoporosis. ,1. MYTH: ... many more women who may develop this condition, theres also a ... In fact, roughly 2 million men suffer from osteoporosis, accounting for ...
Cached Medicine News:Health News:New Cancer Therapy That can Be Less Painful 2Health News:Children Using Slide in Playground Treated for Exposure to Poisoning 2Health News:HIV Survival Improves If Patients Stay in Care 2Health News:7 Common Myths About Osteoporosis 2Health News:7 Common Myths About Osteoporosis 3
Used for common bile duct exploration. Supplied sterile in peel-open packages. Intended for one-time use....
... with the MAMMOTOME® HH (Hand ... invasive procedure using ultrasound imaging ... images to locate breast abnormalities, ... and map the area you ...
... Provides reliable strength for temporary wound ... which compliant and stretchable support material ... transudate is not required. Predictable absorption. ... be inert, nonantigenic, and nonpyrogenic. ,VICRYL ...
... Mesh plugs perform best when the ... contact with a smooth wall of highly ... means less tissue remodeling to help stabilize ... fills more of the defect with gentle ...
Medicine Products: